{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1381699995603071111.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Yoshiiku Kawakami"}],"foaf:familyName":[{"@value":"Kawakami"}],"foaf:givenName":[{"@value":"Yoshiiku"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1361699995603071104","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1007/s12328-009-0063-2"},{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12328-009-0063-2.pdf"},{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s12328-009-0063-2/fulltext.html"},{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12328-009-0063-2"},{"@type":"PMID","@value":"26192299"}],"notation":[{"@value":"Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12328-009-0063-2_9hRBXE0aP4Ngl4rW1oF3jXwWYh3"},{"@type":"OPENAIRE","@value":"doi_dedup___::0fa3e73d30efc16e7f64d8f6d9a72ecc_9hRBXE0aP4Ngl4rW1oF3jXwWYh3"}]}